Histogenics Stock Price, News & Analysis (NASDAQ:HSGX)

$2.78 -0.14 (-4.79 %)
(As of 01/16/2018 08:40 AM ET)
Previous Close$2.92
Today's Range$2.77 - $3.13
52-Week Range$1.45 - $3.13
Volume506,700 shs
Average Volume293,800 shs
Market Capitalization$66.92 million
P/E Ratio-2.01
Dividend YieldN/A
Beta1.43

About Histogenics (NASDAQ:HSGX)

Histogenics logoHistogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient's own cartilage cells through a series of tissue engineering processes. The patient's cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company's Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

Receive HSGX News and Ratings via Email

Sign-up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HSGX
CUSIPN/A
Phone781-547-7900

Debt

Debt-to-Equity RatioN/A
Current Ratio4.42%
Quick Ratio4.42%

Price-To-Earnings

Trailing P/E Ratio-2.01449275362319
Forward P/E Ratio-2.48
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.85 per share
Price / Book3.27

Profitability

Trailing EPS($1.38)
Net Income$-16,200,000.00
Net MarginsN/A
Return on Equity-658.91%
Return on Assets-106.38%

Miscellaneous

Employees47
Outstanding Shares24,070,000

Histogenics (NASDAQ:HSGX) Frequently Asked Questions

What is Histogenics' stock symbol?

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) posted its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.07. View Histogenics' Earnings History.

When will Histogenics make its next earnings announcement?

Histogenics is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for Histogenics.

Where is Histogenics' stock going? Where will Histogenics' stock price be in 2018?

2 equities research analysts have issued 1-year target prices for Histogenics' stock. Their predictions range from $4.00 to $4.00. On average, they anticipate Histogenics' stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Histogenics.

Who are some of Histogenics' key competitors?

Who are Histogenics' key executives?

Histogenics' management team includes the folowing people:

  • Garheng Kong M.D. Ph.D., Independent Chairman of the Board (Age 41)
  • Adam Gridley, President, Chief Executive Officer, Director (Age 45)
  • Jonathan I. Lieber, Chief Financial Officer (Age 48)
  • Stephen Richard Kennedy, Chief Operating Officer, Executive Vice President (Age 60)
  • Joshua J. Baltzell, Independent Director (Age 47)
  • David N. Gill, Independent Director (Age 62)
  • John H. Johnson, Independent Director (Age 58)
  • Michael Lewis, Independent Director (Age 58)
  • Kevin L. Rakin, Independent Director (Age 57)

When did Histogenics IPO?

(HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy Histogenics stock?

Shares of Histogenics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Histogenics' stock price today?

One share of Histogenics stock can currently be purchased for approximately $2.78.

How big of a company is Histogenics?

Histogenics has a market capitalization of $66.92 million. The biotechnology company earns $-16,200,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Histogenics employs 47 workers across the globe.

How can I contact Histogenics?

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]


MarketBeat Community Rating for Histogenics (HSGX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Histogenics (NASDAQ:HSGX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.80
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$3.75$4.00$5.88
Price Target Upside: 94.17% upside88.44% upside123.11% upside249.70% upside

Histogenics (NASDAQ:HSGX) Consensus Price Target History

Price Target History for Histogenics (NASDAQ:HSGX)

Histogenics (NASDAQ:HSGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/27/2017HC WainwrightSet Price TargetBuy$4.00LowView Rating Details
12/21/2017Canaccord GenuityReiterated RatingBuy$4.00LowView Rating Details
9/19/2016Needham & Company LLCBoost Price TargetBuy$8.00 -> $11.00N/AView Rating Details
9/7/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
8/11/2016BTIG ResearchUpgradeNeutral -> Buy$3.50N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Histogenics (NASDAQ:HSGX) Earnings History and Estimates Chart

Earnings by Quarter for Histogenics (NASDAQ:HSGX)

Histogenics (NASDAQ HSGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.23)N/AView Earnings Details
11/9/2017Q3 2017($0.30)($0.23)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.31)($0.25)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.34)($0.27)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.47)($1.60)ViewN/AView Earnings Details
11/10/2016Q316($0.62)($0.70)ViewListenView Earnings Details
8/11/2016Q216($0.60)($0.61)ViewListenView Earnings Details
5/12/2016Q116($0.59)($0.60)ViewListenView Earnings Details
3/10/2016Q415($0.59)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.47)($0.61)ViewListenView Earnings Details
8/12/2015Q215($0.49)($0.58)ViewListenView Earnings Details
5/14/2015Q115($1.34)($0.60)ViewListenView Earnings Details
2/26/2015Q414$0.66$0.54ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Histogenics (NASDAQ:HSGX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.12 EPS
Next Year EPS Consensus Estimate: $-0.82 EPS

Dividends

Dividend History for Histogenics (NASDAQ:HSGX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Histogenics (NASDAQ HSGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 23.80%
Institutional Ownership Percentage: 44.98%
Insider Trades by Quarter for Histogenics (NASDAQ:HSGX)
Institutional Ownership by Quarter for Histogenics (NASDAQ:HSGX)

Histogenics (NASDAQ HSGX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2017David N GillDirectorBuy3,000$1.81$5,430.0014,000View SEC Filing  
5/16/2017David N GillDirectorBuy3,000$1.68$5,040.0011,000View SEC Filing  
12/15/2016David N GillDirectorBuy3,000$1.65$4,950.008,000View SEC Filing  
12/9/2016David N GillDirectorBuy5,000$1.92$9,600.005,000View SEC Filing  
12/2/2016Jonathan I LieberCFOBuy5,000$1.95$9,750.005,000View SEC Filing  
12/1/2016Adam GridleyInsiderBuy5,000$2.01$10,050.005,000View SEC Filing  
9/29/2016Split Rock Partners Ii, LpMajor ShareholderBuy276,801$2.25$622,802.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Histogenics (NASDAQ HSGX) News Headlines

Source:
DateHeadline
What Should You Know About Histogenics Corporation’s (NASDAQ:HSGX) Earnings Trajectory?What Should You Know About Histogenics Corporation’s (NASDAQ:HSGX) Earnings Trajectory?
finance.yahoo.com - January 10 at 11:30 AM
Histogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese Neocart AgreementHistogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement
finance.yahoo.com - January 9 at 11:10 AM
Histogenics (HSGX) Lowered to "Hold" at Zacks Investment ResearchHistogenics (HSGX) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - December 28 at 11:42 PM
HC Wainwright Reiterates $4.00 Price Target for Histogenics (HSGX)HC Wainwright Reiterates $4.00 Price Target for Histogenics (HSGX)
www.americanbankingnews.com - December 28 at 10:14 PM
Histogenics (HSGX): HC Wainwright Sees The Japan Agreement As A Key Step for NeoCartHistogenics (HSGX): HC Wainwright Sees The Japan Agreement As A Key Step for NeoCart
www.streetinsider.com - December 28 at 4:29 PM
Comparing BioDelivery Sciences International (BDSI) & Histogenics (HSGX)Comparing BioDelivery Sciences International (BDSI) & Histogenics (HSGX)
www.americanbankingnews.com - December 24 at 8:05 AM
Histogenics (HSGX) Rating Reiterated by Canaccord GenuityHistogenics (HSGX) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - December 22 at 1:38 PM
BRIEF-MEDINET signs license contract for NeoCart with HistogenicsBRIEF-MEDINET signs license contract for NeoCart with Histogenics
www.reuters.com - December 21 at 11:27 AM
Interested In Histogenics Corporation (NASDAQ:HSGX)? Here’s What Its Recent Track-Record Looks LikeInterested In Histogenics Corporation (NASDAQ:HSGX)? Here’s What Its Recent Track-Record Looks Like
finance.yahoo.com - December 15 at 11:54 AM
 Analysts Anticipate Histogenics Corporation (HSGX) Will Post Earnings of -$0.22 Per Share Analysts Anticipate Histogenics Corporation (HSGX) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - December 15 at 11:06 AM
-$0.22 EPS Expected for Histogenics Corporation (HSGX) This Quarter-$0.22 EPS Expected for Histogenics Corporation (HSGX) This Quarter
www.americanbankingnews.com - November 27 at 7:48 AM
Histogenics Corporation (HSGX) Rating Increased to Buy at Zacks Investment ResearchHistogenics Corporation (HSGX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - November 25 at 9:32 AM
Histogenics Corporation (HSGX) Rating Reiterated by HC WainwrightHistogenics Corporation (HSGX) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - November 21 at 4:41 PM
Analyzing Histogenics Corporation (HSGX) and Innocoll Holdings PLC (INNL)Analyzing Histogenics Corporation (HSGX) and Innocoll Holdings PLC (INNL)
www.americanbankingnews.com - November 18 at 5:20 PM
Histogenics Corporation Announces Third Quarter 2017 Financial and Operating ResultsHistogenics Corporation Announces Third Quarter 2017 Financial and Operating Results
finance.yahoo.com - November 11 at 9:51 AM
Histogenics Corporation (HSGX) Releases  Earnings Results, Beats Expectations By $0.07 EPSHistogenics Corporation (HSGX) Releases Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - November 10 at 7:32 PM
Histogenics Corporation (HSGX) & Its Peers Critical AnalysisHistogenics Corporation (HSGX) & Its Peers Critical Analysis
www.americanbankingnews.com - November 8 at 11:58 AM
Histogenics Corporation (HSGX) to Release Quarterly Earnings on ThursdayHistogenics Corporation (HSGX) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - November 2 at 1:28 AM
Histogenics Corporation (HSGX): Time For A Financial Health CheckHistogenics Corporation (HSGX): Time For A Financial Health Check
finance.yahoo.com - October 28 at 6:42 AM
Histogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017Histogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017
finance.yahoo.com - October 26 at 11:47 AM
Zacks: Brokerages Expect Histogenics Corporation (HSGX) Will Announce Earnings of -$0.30 Per ShareZacks: Brokerages Expect Histogenics Corporation (HSGX) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - October 19 at 10:30 PM
Histogenics Corporation (HSGX) vs. The Competition Critical ReviewHistogenics Corporation (HSGX) vs. The Competition Critical Review
www.americanbankingnews.com - October 19 at 2:10 AM
Zacks Investment Research Lowers Histogenics Corporation (HSGX) to HoldZacks Investment Research Lowers Histogenics Corporation (HSGX) to Hold
www.americanbankingnews.com - October 17 at 12:34 AM
Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating OfficerHistogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer
finance.yahoo.com - October 13 at 12:08 AM
Histogenics Corporation (HSGX) Presents At Cell & Gene Meeting On The Mesa - SlideshowHistogenics Corporation (HSGX) Presents At Cell & Gene Meeting On The Mesa - Slideshow
seekingalpha.com - October 6 at 8:07 PM
Critical Survey: Histogenics Corporation (HSGX) vs. Theravance Biopharma (TBPH)Critical Survey: Histogenics Corporation (HSGX) vs. Theravance Biopharma (TBPH)
www.americanbankingnews.com - October 5 at 9:46 AM
Histogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage TestingHistogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage Testing
finance.yahoo.com - October 2 at 6:32 PM
Histogenics Corporation to Present at the 2017 Cell & Gene Meeting on the MesaHistogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa
feeds.benzinga.com - September 26 at 9:35 AM
How Should You Think About Histogenics Corporation’s (HSGX) Risks?How Should You Think About Histogenics Corporation’s (HSGX) Risks?
finance.yahoo.com - September 14 at 6:10 AM
Histogenics Corporation (HSGX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowHistogenics Corporation (HSGX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 12 at 11:50 PM
Histogenics (HSGX) Presents At Bairds 2017 Global Healthcare Conference - SlideshowHistogenics (HSGX) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 10 at 12:03 AM
Histogenics Corporation (HSGX) Receives Consensus Recommendation of "Hold" from AnalystsHistogenics Corporation (HSGX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 23 at 12:30 AM
Histogenics Corporation (HSGX) Given a $4.00 Price Target at HC WainwrightHistogenics Corporation (HSGX) Given a $4.00 Price Target at HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
Edited Transcript of HSGX earnings conference call or presentation 10-Aug-17 12:30pm GMTEdited Transcript of HSGX earnings conference call or presentation 10-Aug-17 12:30pm GMT
finance.yahoo.com - August 11 at 8:04 PM
Histogenics Corporations (HSGX) Buy Rating Reaffirmed at Canaccord GenuityHistogenics Corporation's (HSGX) Buy Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - August 11 at 4:48 PM
Histogenics Corporation Announces Second Quarter 2017 Financial and Operating ResultsHistogenics Corporation Announces Second Quarter 2017 Financial and Operating Results
www.nasdaq.com - August 11 at 2:38 AM
Histogenics Corporations (HSGX) CEO Adam Gridley on Q2 2017 Results - Earnings Call TranscriptHistogenics Corporation's (HSGX) CEO Adam Gridley on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 2:38 AM
Histogenics reports 2Q lossHistogenics reports 2Q loss
finance.yahoo.com - August 11 at 2:38 AM
Histogenics Corporation (HSGX) Releases Quarterly  Earnings Results, Beats Expectations By $0.06 EPSHistogenics Corporation (HSGX) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - August 10 at 7:46 PM
Histogenics Corporation (HSGX) Expected to Announce Earnings of -$0.31 Per ShareHistogenics Corporation (HSGX) Expected to Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - August 6 at 10:26 AM
Histogenics Corporation (NASDAQ:HSGX) Set to Announce Quarterly Earnings on ThursdayHistogenics Corporation (NASDAQ:HSGX) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:16 AM
Contrasting Histogenics Corporation (NASDAQ:HSGX) and Galena Biopharma (GALE)Contrasting Histogenics Corporation (NASDAQ:HSGX) and Galena Biopharma (GALE)
www.americanbankingnews.com - July 29 at 7:26 AM
Histogenics Corporation (HSGX) Given Consensus Recommendation of "Hold" by BrokeragesHistogenics Corporation (HSGX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 29 at 12:43 AM
Histogenics Corporation to Announce Second Quarter 2017 Financial Results on August 10, 2017Histogenics Corporation to Announce Second Quarter 2017 Financial Results on August 10, 2017
finance.yahoo.com - July 27 at 8:12 PM
Histogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth ConferenceHistogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth Conference
finance.yahoo.com - July 26 at 3:58 PM
 Analysts Expect Histogenics Corporation (NASDAQ:HSGX) to Post -$0.31 EPS Analysts Expect Histogenics Corporation (NASDAQ:HSGX) to Post -$0.31 EPS
www.americanbankingnews.com - July 17 at 10:57 AM
Histogenics Announces Publication of Data From Collagen and Chondrocyte 3-D Bioprinting StudyHistogenics Announces Publication of Data From Collagen and Chondrocyte 3-D Bioprinting Study
finance.yahoo.com - July 11 at 11:12 PM
Histogenics Corporation (NASDAQ:HSGX) Given Consensus Recommendation of "Buy" by BrokeragesHistogenics Corporation (NASDAQ:HSGX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 4 at 12:33 AM
Histogenics (HSGX) Completes Enrollment in Phase 3 Trial of Neocart to Treat Knee Cartilage DamageHistogenics (HSGX) Completes Enrollment in Phase 3 Trial of Neocart to Treat Knee Cartilage Damage
www.streetinsider.com - June 29 at 12:07 AM
Histogenics (HSGX) CEO Adam Gridley on Q1 2017 Results - Earnings Call TranscriptHistogenics' (HSGX) CEO Adam Gridley on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 6:21 PM

SEC Filings

Histogenics (NASDAQ:HSGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Histogenics (NASDAQ:HSGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Histogenics (NASDAQ HSGX) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.